Intravitreal Ranibizumab In The Treatment Of Pigment Epithelial Detachment

1. Tsung-Yu Ho^1,2
2. Shih-Jen Chen^1,2
3. Lee-Jen Chen³

¹Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan
²National Yang-Ming University School of Medicine, Taipei, Taiwan
³Department of Ophthalmology, Mackay Memorial Hospital, Taipei, Taiwan

Purpose: To determine the prognostic factor in patients with PED secondary to age-related macular degeneration after intravitreal ranibizumab.

Methods: Eleven patients treated at monthly intervals for 6 months. Endpoint was resolution of PED.

Results: The mean visual acuity and PED height improved significantly (10±7.5 letters gain and 206±164 um decrease, p<0.005). Among the 7 patients with retinal angiomatous proliferation (RAP), those with PED size smaller than 10mm2 received less than 4 injections while others with PED greater than 10 mm2 had 5.2 injections. The other 4 isolated PED patients, all with less than 8mm2 of PED in size, did not resolve after 6 injections.

Conclusions: PED size is a prognostic factor for PED regression in patients with RAP but not for patients with isolated PED.